BioMEMS and Biomedical Nanotechnology

• Biosensor
• Nanomaterial
• Nanotube
• Sensor
• biomedical application
• biomedical applications
• biomedicine
• bionanotechnology
• biotechnology
• carbon nanotubes
• diagnostics
• mechanics
• microelectromechanical system (MEMS)
• nanotechnology
• tissue

• Department of Biomedical Engineering, University of Texas Health Science Center, Houston

  Mauro Ferrari

• University of Texas M.D. Anderson Cancer Center, Houston

  Mauro Ferrari

• Rice University, Houston

  Mauro Ferrari

• University of Texas Medical Branch, Galveston

  Mauro Ferrari

• Texas Alliance for NanoHealth, Houston

  Mauro Ferrari

• Biomedical Engineering, University of California, Irvine

  Abraham P. Lee

• Chemical and Biomolecular Engineering, The Ohio State University, USA

  L. James Lee

Abe Lee has been working on micro/ and nanotechnology for biomedical and biotech applications since 1992. His recent research focuses on the development of integrated micro and nano fluidic chip processors for the following applications: point-of-care diagnostics, "smart" nanomedicine for early detection and treatment, stem cell biology and therapeutics, the synthesis of novel and pure materials, and biosensors to detect environmental and terrorism threats. He has over 30 peer reviewed publications and over 30 issued US patents. I am also subject editor for the Journal of Microelectromechanical Systems and member of the International Advisory Editorial Board for the Lab on a Chip journal.

Jim Lee's research interest includes BioMEMS/NEMS, and polymer micro/nanotechnology. In the last 4 years, he has over 20 refereed journal publications, 2 book chapters, and 5 patents in these areas. He is now leading an NSF Nanoscale Science and Engineering Center for Affordable Nanoengineering of Polymer Biomedical Devices at OSU.

Professor Mauro Ferrari is a pioneer in the fields of bioMEMS and biomedical nanotechnology. As a leading academic, a dedicated entrepreneur, and a vision setter for the Nation's premier Federal programs in nanomedicine, he brings a three-fold vantage perspective to his roles as Editor-in-Chief for this work. Dr. Ferrari has authored or co-authored over 150 scientific publications, 6 books, and over 20 US and

International patents. Dr. Ferrari is also Editor-in-Chief of Biomedical Microdevices and series editor of the new Springer series on Emerging Biomedical Technologies.

Several private sector companies originated from his laboratories at the Ohio State University and the University of California at Berkeley over the years. On a Federal assignment as Special

Expert in Nanotechnology and Eminent Scholar, he has provided the scientific leadership for the development of the Alliance for Cancer Nanotechnology of the National Cancer Institute, the world-largest medical nanotechnology operation to date. Dr. Ferrari trained in mathematical physics in Italy, obtained his Master's and Ph.D. in Mechanical

Engineering at Berkeley, attended medical school at The Ohio State University, and served in faculty positions in Materials Science and Engineering, and Civil and Environmental Engineering in Berkeley, where he was first tenured. At Ohio State he currently serves as Professor of Internal Medicine, Division of Hematology and Oncology, as Edgar Hendrickson Professor of Biomedical Engineering, and as Professor of Mechanical Engineering. He is Associate Director of the Dorothy M. Davis

Heart and Lung Research Institute, and the University's Associate Vice President for Health Science, Technology and Commercialization.

Policies and ethics